EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[°ÇÁø °ü·Ã ´º½º (±¹³»)]

[2013-10-22. ¸Ó´ÏÅõµ¥ÀÌ] °Ç°­°ËÁø ¼ö¸é³»½Ã°æ ±ú°í 'È­µé¦', Àå¼Ò°¡¡¦

¿©¼º Á÷ÀåÀÎ A¾¾(42¼¼)´Â Áö³­ 21ÀÏ ¼­¿ï ¸íµ¿ Áß¾Ó¿ìü±¹ °Ç¹°¿¡ ÀÖ´Â ¼­¿ïÁß¾ÓŬ¸®´Ð¿¡¼­ °Ç°­°ËÁøÀ» ¹ÞÀ¸¸ç Ȳ´çÇÑ °æÇèÀ» Çß´Ù. À§Àå ³»½Ã°æÀÌ °ï¿å½º·¯¿ö ¼ö¸é ³»½Ã°æÀ» ¼±ÅÃÇÑ °Ô µÇ·¹ È­±ÙÀ̾ú´Ù. A¾¾°¡ ¼ö¸é ³»½Ã°æÀ» ¸¶Ä¡°í Á¤½ÅÀ» Â÷¸° °÷Àº ȸº¹½Ç(¼ö¸é½Ç)ÀÌ ¾Æ´Ï¶ó ´ÙÀ½ °ËÁøÀ» À§ÇØ ´ë±âÇÏ´Â ¼ÒÆÄ¿´´Ù.

°°Àº ½Ã°£¿¡ ÇÔ²² °Ç°­°ËÁøÀ» ¹ÞÀº Á÷À嵿·áµéÀÌ ÀÚ½ÅÀÇ ÈåÆ®·¯Áø ¸ð½ÀÀ» ºÃÀ» °Í¸¸ °°¾Æ A¾¾´Â ½ÉÇÑ ¼öÄ¡½ÉÀ» ´À²¼´Ù. A¾¾´Â ºñ¸ù»ç¸ù°£¿¡ Èû°ã°Ô ³ª¸ÓÁö °Ç°­°ËÁøÀ» ¸¶ÃÆ´Ù. ±×·¯³ª Á¤ÀÛ ¼ö¸é ³»½Ã°æ ÈÄÀ¯ÁõÀ¸·Î °ËÁø ¸¶Áö¸·¿¡ Àü¹®ÀÇ°¡ °ËÁø °á°ú¸¦ ³õ°í ÇØÁØ »ó´ã ³»¿ëÀº ÀüÇô ±â¾ïÇÏÁö ¸øÇß´Ù. ¹ÝÂÊÂ¥¸® °ËÁøÀ̾ú´Ù.


[2012-6-5. ÇÑ°Ü·¹] °úÀ× °Ç°­°ËÁøÀÇ ÈÄÀ¯Áõ, °¡Â¥º´¡¤¸¶À½ÀÇ º´¡¤¾à¹° ³²¿ë (link2)


[2014-10-11. ÀÇÇù½Å¹®] °³ÀÎÂ÷ ¹«½ÃÇÑ °Ç°­°ËÁø, ´õ ÀÌ»ó ÀÇ¹Ì ¾ø´Ù

2014³â 10¿ù 10ÀÏ EndoTODAY¸¦ ÅëÇÏ¿© '°ÇÁø À§³»½Ã°æÀ» ¸î ¼¼¿¡ Áß´ÜÇÒ °ÍÀΰ¡?'¿¡ ´ëÇÏ¿© ³íÇÏ¿´½À´Ï´Ù. ±×·±µ¥ ¸¶Ä§ ´ÙÀ½ ³¯ ÀÇÇù½Å¹®¿¡ '°³ÀÎÂ÷ ¹«½ÃÇÑ °Ç°­°ËÁø, ´õ ÀÌ»ó ÀÇ¹Ì ¾ø´Ù' ´Â Á¦¸ñÀÇ ±â»ç°¡ ½Ç·È½À´Ï´Ù. À߸øµÈ °Ç°­°ËÁøÀº °³¼±ÀÇ ´ë»óÀÌ ¾Æ´Ï¶ó ŸÆÄÀÇ ´ë»óÀ̶ó´Â ÁÖÀåÀÌ ¼³µæ·ÂÀÖ¾î º¸ÀÔ´Ï´Ù.

ÀÚµ¿Â÷¿¡¼­ ÀÌ»óÇÑ ¼Ò¸®°¡ ³ª´Â °Í °°¾Æ Ä«¼¾ÅÍ¿¡¼­ Á¡°ËÀ» ¹Þ½À´Ï´Ù. ±â»ç´ÔÀÌ Á¦ Â÷¸¦ À̸® Àú¸® »ìÆ캸°í 'Å« ÀÌ»óÀÌ ¾øÀ¸´Ï Á» ´õ Ÿ º¸¶ó'°í ±ÇÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. ÀÌ ¶§´Â µ·À» ³»Áö ¾Ê½À´Ï´Ù. ŸÀÌ¾î °ø±â¸¦ ³Ö¾îÁ־ µ·À» ³»Áö ¾Ê½À´Ï´Ù. ¿£Áø¿ÀÀÏÀÌ¶óµµ ¹Ù²ã¾ß µ·À» ³À´Ï´Ù. ¼­ºñ½º¿¡´Â µ·À» ³»Áö ¾Ê´Â °ÍÀÌ ¿ì¸®³ª¶ó ¹®È­ÀÔ´Ï´Ù. À§¾Ï °¡Á··Â¿¡ ´ëÇÑ »ó´ãÀº µ·À» ¹Þ±â ¾î·Æ½À´Ï´Ù. Ç÷¾×°Ë»ç¶óµµ ÇØ¾ß µ·À» ¹Þ½À´Ï´Ù. ÀÌ·± ¹®È­, ÀÌ·± ¼ö°¡±¸Á¶¿¡¼­´Â ¸ÂÃãÇü °Ç°­°ËÁøÀº ¾î·Á¿ï ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. ¾îµð¼­ºÎÅÍ ¸ÅµìÀ» Ç®¾î¾ß ÇÒ±î¿ä?

"°¢ °³ÀÎÀÌ °®´Â À§Çè¿äÀÎÀÌ ÀüÇô °í·ÁµÇÁö ¾Ê´Â ÇüÅÂÀÇ °Ç°­°ËÁøÀº, ÀÌÁ¦ °³¼± Á¤µµ°¡ ¾Æ´Ï¶ó ŸÆÄµÅ¾ß ÇÒ ½Ã±â°¡ ¾Æ´Ñ°¡ »ý°¢ÇÕ´Ï´Ù." ÀÏÁ¤ÇÑ °ËÁø Ç׸ñÀ¸·Î ´©±¸¿¡°Ô³ª Àû¿ëµÇ´Â ÇöÇà °Ç°­°ËÁøÀÇ ½ÇÈ¿¼ºÀÌ Å©°Ô ¶³¾îÁø´Ù´Â ÁöÀûÀÌ ³ª¿Ô´Ù. ¿ªÇÐÀû Ư¼ºÀ» °í·ÁÇÑ ½Ã½ºÅÛ °³¹ß·Î °ËÁøÀÇ ÁúÀ» ²ø¾î¿Ã·Á¾ß ÇÑ´Ù´Â ÁÖÀåÀÌ´Ù.

½Åȣö ¼º±Õ°üÀÇ´ë ±³¼ö(°­ºÏ»ï¼ºº´¿ø °¡Á¤ÀÇÇаú)´Â 10ÀÏ ¼­¿ï ±×·£µåÈúÆ°È£ÅÚ¿¡¼­ ¿­¸° 2014 ´ëÇÑ°¡Á¤ÀÇÇÐȸ Ãß°èÇмú´ëȸ¿¡¼­ '°Ç°­°ËÁøÀÇ ¿øÄ¢°ú °¡Á¤ÀÇÇÐÀÇ ¿ªÇÒ'À» ÁÖÁ¦·Î ÀÌ °°ÀÌ ¹àÇû´Ù. À̳¯ ½Å ±³¼ö´Â ³ëÀÎÃþ°ú ÀþÀºÃþ, ³²³à Â÷ÀÌ°¡ °ÅÀÇ ¹«½ÃµÈ ÇüÅÂÀÇ °Ç°­°ËÁøÀ» µÎ°í "¿Ü±¹ÀÇ ¿¹¸¦ ºÁµµ ´õ ÀÌ»ó Àǹ̰¡ ¾ø´Ù"°í ´Ü¾ðÇß´Ù. ±×·¯¸é¼­ "°Ç°­°ËÁøÀÌ Áø·áÇàÀ§·Î ÀÎÇÑ ÀûÀÚ¸¦ º¸ÀüÇÏ´Â ¼ö´ÜÀ¸·Î ¿©°ÜÁö°í ÀÖ´Â ¾î·Á¿î ÀÇ·á°è ȯ°æ¿¡¼­ ¹«¸®°¡ µû¸¦ ¼ö ÀÖÁö¸¸, Á¶±Ý¸¸ ³ë·ÂÇϸé Áö±Ýº¸´Ù ÈξÀ ³ªÀº °ËÁøÀÌ ÀÌ·ïÁú ¼ö ÀÖ´Ù"°í ¸ñ¼Ò¸®¸¦ ³ô¿´´Ù.

´ëºÎºÐÀÇ °Ç°­°ËÁøÀÌ Áý´Ü ÇüÅ·Π½Ç½ÃµÅ »çÀü °Ç°­»ó´ãÀ̳ª ½ÅüÁøÂû µîÀÌ Çü½ÄÀûÀ¸·Î ½ÃÇàµÇ°Å³ª »ý·«µÇ°í ÀÖ´Â Á¡µµ ¹®Á¦Á¡À¸·Î °Å·ÐµÆ´Ù. ÀÌ·¯ÇÑ ¹®Á¦ÀÇ ±Ùº» ¿øÀÎÀº ȯÀÚ ¸é´ã°ú °ËÁøÀ» º´ÇàÇÔÀ¸·Î½á ¾ò¾îÁö´Â ¿¹¹æ¼­ºñ½º¿¡ ´ëÇÑ ¼ö°¡°¡ °áÁ¤µÅ ÀÖÁö ¾Ê¾Æ ÇàÀ§¿¡ ´ëÇÑ º¸»óÀ» ¹ÞÀ» ¼ö ¾ø±â ¶§¹®ÀÌ´Ù. ÀÇ»ç ÀÔÀå¿¡¼­´Â ¸·»ó ¸é´ãÀ» ½ÃµµÇÏ·Á Çصµ Çö½ÇÀûÀ¸·Î ¿¹¹æ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇÑ ½Ã°£À» È®º¸Çϱ⠾î·Æ´Ù. ½Å ±³¼ö´Â "´Ü¼øÇÑ Ç÷¾× ¹× ´¢°Ë»ç, ¿µ»óÃÔ¿µ µîÀÇ °Ë»ç À§ÁÖ·Î °ËÁøÀÌ µÇ´Ùº¸´Ï °Ë»ç¸¦ ¹Þ´Â ´ç»çÀÚµµ ÀÇ»ç¿ÍÀÇ »çÀü »ó´ãÀ̳ª ½ÅüÁøÂû º¸´Ù´Â °¢Á¾ °Ë»ç°¡ °ËÁøÀÇ º»ÁúÀÎ °ÍÀ¸·Î ¿ÀÇØÇÏ´Â °æ¿ì°¡ ¸¹´Ù"¸ç ¾ÈŸ±î¿òÀ» Ç¥½ÃÇß´Ù.

ÇØ°á ¹æ¾ÈÀ¸·Î´Â ¡ã°³ÀÎÀÇ ¿¬·Éº°, ¼ºº°, À§Çè¿äÀκ° Ư¼ºÀ» °í·ÁÇÑ ¼±ÅÃÀû °ËÁøÇ׸ñ äÅà ¡ã°ËÁø½Ã ¹®ÁøÀ» ÅëÇÑ °Ç°­»ó´ã, ÁøÂû °­È­ ¡ãȯÀÚ±³À°°ú ¿¹¹æÁ¢Á¾ µîÀ» Æ÷ÇÔ½ÃÅ°´Â °ËÁø ÇüÅ·ÎÀÇ °³¼± µîÀ» Á¦½ÃÇß´Ù...


À§ÃÔ¿µ¿¡¼­ ¹ß°ßµÈ ÀÌ»ó¼Ò°ßÀ¸·Î ÀÇ·ÚµÈ È¯ÀÚÀÔ´Ï´Ù. °ú°ÅºÎÅÍ À§ SMT·Î ³»½Ã°æ ÃßÀû°Ë»ç¸¦ ¹Þ´ø ºÐÀ̾ú½À´Ï´Ù. ±×·±µ¥ °Ç°­°ËÁø ¼¾ÅÍ¿¡¼­ ¹«½ÉÄÚ À§ÃÔ¿µÀ» ¹Þ¾Ò°í ¹º°¡ ¹ß°ßµÇ¾î °ÆÁ¤½º·± ´«ºûÀ¸·Î ¿Ü·¡¸¦ ã¾Æ¿À¼Ì½À´Ï´Ù. ȯÀÚÀÇ º´·ÂÀ» ¹°¾îº¸¾Ò´õ¶ó¸é À§ÃÔ¿µÀÌ ¾Æ´Ï¶ó À§³»½Ã°æÀ» ±ÇÇÏ´Â °ÍÀÌ ¿Ç¾Ò´ø ºÐÀÔ´Ï´Ù. À§³»½Ã°æ °Ë»ç¸¦ ÇÏ¿´°í °ú°ÅºÎÅÍ ÀÖ¾ú´ø Á¡¸·ÇÏÁ¾¾çÀÌ ±×´ë·Î ÀÖ´Ù´Â °ÍÀ» È®ÀÎÇÏ°í 2³â ÈÄ 'À§³»½Ã°æ' °Ë»ç¸¦ ¹Þµµ·Ï ±ÇÇÏ¿´½À´Ï´Ù. °á±¹ ȯÀÚ´Â ºÒÇÊ¿äÇÑ À§ÃÔ¿µ, ºÒÇÊ¿äÇÑ radiation, ºÒÇÊ¿äÇÑ °ÆÁ¤, ºÒÇÊ¿äÇÑ ¿Ü·¡¹æ¹®, ºÒÇÊ¿äÇÑ ºñ¿ëÁöºÒÀ» Çß´ø ¼ÀÀÔ´Ï´Ù.

°ú°Å·ÂÀ» È®ÀÎÇÏÁö ¾Ê°í ¹«ÀÛÁ¤ ½ÃÇàÇÏ´Â °Ç°­°ËÁø¿¡ ¹Ý´ëÇÕ´Ï´Ù. ºñ¿ëÀ» µûÁö±â ¾Õ¼­ ÀÇ»çÀÇ ±âº» ŵµ ¹®Á¦ ¾Æ´Ò±î¿ä? ¸ðµç Àǻ簡 ±âº» ŵµ¸¦ Àß ÁöÅ°´Â °ÍºÎÅÍ ¾îó±¸´Ï ¾ø´Â ÀÇ·á¼ö°¡ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù. ÁøÁ¤¼ºÀÌ ÃÖ¿ì¼±À̴ϱî¿ä.


[2013-11-14. TV Á¶¼±] ´ëÇü°Ç°­°ËÁø¼¾ÅÍ, ÀÇ»ç ¾øÀÌ ÃÊÀ½ÆÄ °Ë»ç ÀÇ·á¹ý À§¹Ý Çã´Ù

[¾ÞÄ¿] Ȥ½Ã ±×·±°¡ ¾Æ´Ñ°¡ Çߴµ¥ ÁøÂ¥ ±×·¨½À´Ï´Ù. Àúµµ ¸çÄ¥µÚ¿¡ °Ç°­ °ËÁøÀ» ¹ÞÀ¸·Á°í Çϴµ¥ ´ëÇѹα¹ÀÇ ´ëÇü °Ç°­ °ËÁø ¼¾Å͵éÀÌ ÃÊÀ½ÆÄ °Ë»ç°°Àº Áß¿äÇÑ °Ë»ç¸¦ ÀÇ»ç ¾øÀÌ º´¿ø Á÷¿øÀÌ È¥ÀÚ ÇÏ´Â °ÍÀ¸·Î TV Á¶¼± ÃëÀç °á°ú È®ÀεƽÀ´Ï´Ù. Àǻ簡 Çصµ ¾î·Á¿î °Ë»çÀε¥, ÀÌ°Ç ÀÇ·á¹ý À§¹ÝÀÔ´Ï´Ù. À̹μ® ±âÀÚÀÇ ´Üµ¶ º¸µµÀÔ´Ï´Ù.
[¸®Æ÷Æ®] ¼­¿ïÀÇ ´ëÇü °Ç°­°ËÁø¼¾ÅÍ. °£ ÃÊÀ½ÆÄ °Ë»ç¸¦ ¹ÞÀ¸·¯ µé¾î¼·´Ï´Ù. ±×·±µ¥ Àǻ簡 ¾Æ´Õ´Ï´Ù. °Ë»ç¸¦ ÇÏ´Â »ç¶÷Àº ¹æ»ç¼±»ç.
[³ìÃë] °ËÁøÀÚ "¹æ»ç¼±»ç½ÃÀݾƿä?"
[³ìÃë] ¹æ»ç¼±»ç "³×." "½°È£Èí ÇϽðí! ÇϾé°Ô º¸ÀÌ´Â ºÎºÐÀº ¿ëÁ¾ÀÌ¿¡¿ä. ¿ö³« À۱⠶§¹®¿¡ Ưº°ÇÑ Àǹ̴ ¾ø¾î¿ä."
ÀÇ»ç´Â óÀ½ºÎÅÍ ³¡±îÁö º¸ÀÌÁú ¾Ê½À´Ï´Ù. ¶Ç´Ù¸¥ °Ç°­°ËÁø¼¾ÅÍ. ½Ä»çÇÑ Áö 8½Ã°£ÀÌ Áö³ª¾ß °Ë»ç¸¦ ¹ÞÀ» ¼ö Àִµ¥, 5½Ã°£ÀÌ ¾ÈÁö³µ´Âµ¥µµ °Ë»ç¸¦ ¹ÞÀ¸¶ó°í ±ÇÇÕ´Ï´Ù.
[³ìÃë] Á÷¿ø "Á¢¼ö Çص帱Å×´Ï±î ¿Ã¶ó°¡¼Å¼­."
¿©±â¼­µµ Àǻ簡 ¾Æ´Ñ ¹æ»ç¼±»ç°¡ °Ç°­°ËÁøÀ» óÀ½ºÎÅÍ ³¡±îÁö ÁøÇàÇÕ´Ï´Ù.
[ÀÎÅͺä] ÃÖÀ±¼± / ¼­¿ï Á¾·Î±¸ "°Ç°­°ËÁø ¿ÀÁøÀ²µµ ¸¹¾Æ¼­ °á°ú°¡ Á¤È®ÇÒ Áö ºÒ¾ÈÇÏÁÒ. °ËÁø ¹ÞÀ» ¶§ ÀÇ»çÀÎÁö ¾Æ´ÑÁö ¹°¾îº¼¼öµµ ¾ø°í, ²²¸§Ä¢ÇØ¿ä."
º¹ÁöºÎ´Â Áö³­ 4¿ù, ¹æ»ç¼±»ç°¡ ´Üµ¶À¸·Î ÇÏ´Â ÃÊÀ½ÆÄ °Ë»ç¸¦ ÀÇ·á¹ý À§¹ÝÀ¸·Î À¯±ÇÇؼ®Çß½À´Ï´Ù. ¡¿ª 5³â, ¹ú±Ý 2õ¸¸ ¿ø ÀÌÇÏÀÇ À§¹ý ÇàÀ§ÀÔ´Ï´Ù.
[ÀÎÅͺä] À±¿ë¼± / ´ëÇÑÀÇ¿øÇùȸÀå "ÀÇ»çµé¿¡ µû¶ó¼­µµ Áø´ÜÀ²¿¡ »ó´çÇÑ Â÷ÀÌ°¡ ³ª´Â ¾î·Á¿î °Ë»ç¸¦ Àǻ簡 ¾Æ´Ñ »ç¶÷ÀÌ È¥ÀÚ ÇÑ´Ù´Â °Ç µ·¹úÀ̸¦ ÇÏ°Ú´Ù´Â °Ì´Ï´Ù."
°Ç°­°ËÁø¼¾Å͵éÀº Àǻ簡 ºÎÁ·ÇÏ´Ù°í Ç׺¯ÇÕ´Ï´Ù.
[³ìÃë] °Ç°­°ËÁø¼¾ÅÍ °ü°èÀÚ "¿ì¸®µµ, ´ëÇк´¿øµéµµ °í¹ÎÇÏ°í ÀÖ½À´Ï´Ù. ¿µ»óÀÇÇаú Àü¹®ÀÇ°¡ ¸¹ÀÌ ³ª¿ÍÁà¾ß Çϴµ¥."
¿¬°£ ¼ö½Ê¾ï¿ø´ëÀÇ ¼öÀÍÀ» ì±â´Â ´ëÇü °Ç°­°ËÁø ¼¾Å͵é, ÀÌ·±Àú·± Çΰ踦 µé¾î Á¦´ë·Î µÈ °ËÁøÀ» ¿Ü¸éÇÏ´Â »çÀÌ, ±¹¹ÎµéÀÇ °Ç°­ÀÌ À§Çù¹Þ°í ÀÖ½À´Ï´Ù


[2013-8-1. Áß¾ÓÀϺ¸] ¾ÏÀÔ´Ï´Ù. °úÀ× Áø´ÜÀÌ °úÀ× °øÆ÷ ºÒ·¯

IHT´Â ¾Ï ºÐ·ù¸¦ ¹Ù²ã¾ß ÇÑ´Ù´Â ¿ä±¸ À̸鿡´Â ¿¬°£ ¼ö½Ê¸¸ ¸íÀÌ ºÒÇÊ¿äÇÏ°í ¶§·Ð ÇØ·Ó±â±îÁö ÇÑ ¾Ï Áø´Ü ¹× Ä¡·á¸¦ ¹Þ°í ÀÖ´Â Çö½ÇÀÌ ÀÖ´Ù°í ÁöÀûÇß´Ù. ƯÈ÷ »ýü ÃÔ¿µ ¹× Æǵ¶ ±â¼úÀÌ ¹ß´ÞÇϸ鼭 ³öµÖµµ ¾ÏÀ¸·Î ¹ßÀüÇϰųª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾ÊÀ» Á¾¾ç±îÁö Á¦°Å ¹× Ä¡·á ´ë»óÀÌ µÇ´Â °Ô ¹®Á¦¶ó°í Çß´Ù. ¿¬±¸ÆÀÀÇ º¸°í¼­µµ Áö³­ 35³â°£ ¾Ï Áø´Ü °Ç¼ö°¡ Å©°Ô ´Ã¾î³­ µ¥ ºñÇØ ¸»±â ¾Ï Áø´Ü ºñÀ²°ú ¾Ï ÀüÀÌ·Î ÀÎÇÑ »ç¸Á·üÀÌ Çö°ÝÈ÷ ÁÙÁö ¾Ê¾Ò´Ù°í ÁöÀûÇß´Ù. ¾ÏÀ̶ó°í º¸±â ¸ðÈ£ÇÑ Ãʱ⠴ܰ谡 ¸¹ÀÌ Áø´ÜµÆ´Ù´Â Àǹ̴Ù.

±¹³»¿¡¼­µµ ³í¶õÀÇ Á߽ɿ¡ ÀÖ´Â °ÍÀÌ °©»ó»ù¾ÏÀÌ´Ù. °©»ó»ù¾ÏÀº »ýÁ¸À²(5³â »ýÁ¸À² 99.8%)ÀÌ ³ôÀº µ¥´Ù ´ë°³ ÀÚ¶ó´Â ¼Óµµµµ ´À¸®´Ù. ±×·¡¼­ ¡®°ÅºÏÀÌ ¾Ï¡¯À̶ó°í ºÒ¸°´Ù. ±×·±µ¥ ÀÌ °©»ó»ù¾Ï ȯÀÚ´Â 2000³â 3288¸í¿¡¼­ 2010³â 3¸¸6021¸íÀ¸·Î 10¹è ÀÌ»óÀ¸·Î ºÒ¾î³µ´Ù. ¹Ý¸é °°Àº ±â°£ Àüü ¾Ï ȯÀÚ´Â 10¸¸1772¸í¿¡¼­ 20¸¸2053¸íÀ¸·Î µÎ ¹è·Î ´Ã¾î³ª´Â µ¥ ±×ÃÆ´Ù. °©ÀÚ±â Çѱ¹ÀÎÀÌ ¾Ï¿¡ Àß °É¸®°Ô µÈ °É±î. ÀÌ¿¡ ´ëÇØ Çѱ¹°³¹ß¿¬±¸¿ø(KDI) À±Èñ¼÷ ¿¬±¸À§¿øÀº ¡°ÃÊÀ½ÆÄ Áø´Ü±â±â°¡ µ¿³× ÀÇ¿ø±îÁö È®´ëµÇ¸é¼­ Áö³ªÄ£ °Ë»ç¸¦ Çϱ⠶§¹®¡±À̶ó°í ÁöÀûÇß´Ù. Áö³­ÇØ 11¿ù ¡®Çѱ¹ 1Â÷ ÀÇ·á ¹ßÀü¹æÇâÀÇ ¸ð»ö¡¯À̶õ º¸°í¼­¸¦ ÅëÇؼ­´Ù. À± ¿¬±¸À§¿øÀº ¡°¿Ü±¹¿¡¼± Áõ»óÀÌ ¾øÀ» °æ¿ì ÃÊÀ½ÆÄ °Ë»ç¸¦ ÇÏÁö ¾Ê´Â °Ô ÀϹÝÀû¡±À̶ó¸ç Çѱ¹ÀÇ °úÀ× Áø·á Çö½ÇÀ» ²¿Áý¾ú´Ù.

ÇÏÁö¸¸ ¹Ý·Ðµµ ÀûÁö ¾Ê´Ù. Àü¾Ï ´Ü°è°Å³ª »ýÁ¸À²ÀÌ ³ô´Ù°í ¾Ë·ÁÁø ¾ÏÀÏÁö¶óµµ Ä¡¸íÀûÀ¸·Î ¹Ù²ð ¼ö ÀÖ´Ù´Â ÀÌÀ¯¿¡¼­´Ù. »ï¼º¼­¿ïº´¿ø ¿À¿µ·û(º´¸®ÇÐ) ±³¼ö´Â ¡°À¯¹æ»óÇdz»¾ÏÀ» Á¦°ÅÇÏÁö ¾Ê°í ±×´ë·Î µÎ¸é ÁÖº¯À¸·Î ÆÛÁö´Â ħÀ±¼º¾ÏÀ¸·Î ¹Ù²ð À§ÇèÀÌ 8~10¹è ³ô¾ÆÁø´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù¡±°í ÁöÀûÇß´Ù. Çö½ÇÀûÀÎ ¾î·Á¿òµµ ÀÖ´Ù. ÀÌÁø¼ö ±¹¸³¾Ï¼¾ÅÍ ¿øÀåÀº ¡°°©»ó»ùÀÇ °æ¿ì »ç¸Á·üÀÌ ³·¾Æ ¹®Á¦°¡ µÇ´Â Ãø¸éÀÌ ÀÖ´Ù¡±¸é¼­µµ ¡°Àǻ簡 ³öµÎÀÚ°í Çصµ ȯÀÚµéÀº °¡¸¸ ÀÖÁö ¾Ê°í Àû±ØÀûÀÎ Ä¡·á¸¦ ¿ä±¸ÇÑ´Ù¡±°í ¸»Çß´Ù. ±¹³»¿¡¼­µµ ¾ÏÀÇ ºÐ·ù¿¡ ´ëÇÑ ³íÀǸ¦ ½ÃÀÛÇØ¾ß ÇÑ´Ù´Â ÀÇ°ßµµ ÀÖ´Ù. »ï¼º¼­¿ïº´¿ø ±è¼±¿í(³»ºÐºñ´ë»ç³»°ú) ±³¼ö´Â ¡°ÇöÀç °úÇбâ¼ú·Î´Â ÀáÀç¾Ï°ú ÁøÇà¾ÏÀ» ±¸º°Çϱ⠾î·Á¿î °ÍÀÌ »ç½ÇÀÌÁö¸¸ ¾ÏÀÇ ºÐ·ù¿¡ ´ëÇØ ÁøÁöÇÑ °í¹ÎÀ» ÇØ¾ß ÇÑ´Ù´Â º¸°í¼­ÀÇ ÃëÁö¿£ µ¿ÀÇÇÑ´Ù¡±°í ¸»Çß´Ù.


[2014-11-11. NEJM Korea thyroid cancer "epidemic" - screening and overdiagnosis]

°í·Á´ë ¾ÈÇü½Ä ±³¼ö´ÔÀÌ NEJM¿¡ ¿ì¸®³ª¶óÀÇ °©»ó¼±¾Ï screening¿Í À¯º´·ü¿¡ ´ëÇÑ Èï¹Ì·Î¿î ±â°í¸¦ Çϼ̽À´Ï´Ù. ÀÇÇнŹ®¿¡´Â Å©°Ô º¸µµµÇ°í ÀÖÁö¸¸ 4´ë ÀÏ°£Áö¿¡¼­´Â °ÅÀÇ ´Ù·ïÁöÁö ¾Ê°í ÀÖ´Â °Í °°½À´Ï´Ù (¼­¿ï°æÁ¦). ³Ê¹« Áß¿äÇÑ ±â°í¶ó°í »ý°¢µÇ¾î Àü¹®À» ¿Å±é´Ï´Ù.

Korea thyroid cancer "epidemic" - screening and overdiagnosis

The Republic of Korea has provided national health insurance to its 50 million citizens since the 1980s. Although health care expenditures in South Korea's single-payer system are relatively low ? accounting for 7.6% of the country's gross domestic product - the system is technologically intensive; among the countries in the Organization for Economic Cooperation and Development, it ranks second in acute care beds per million population, fifth in computed tomography (CT) scanners per million population, and fourth in magnetic resonance imaging (MRI) machines per million population. The country also has a well-developed data infrastructure for both vital statistics (Statistics Korea) and cancer incidence (Korean Central Cancer Registry).

In 1999, the government initiated a national screening program for cancer and other common diseases. This program now provides screening for breast, cervical, colon, gastric, and hepatic cancers free of charge or, for people with above-average income, for a small copayment. Although thyroid-cancer screening was not included in the program, providers frequently chose to offer screening with ultrasonography as an inexpensive add-on for $30 to $50. Many hospitals now market ¡°health checkup¡± programs that include thyroid-cancer screening with ultrasonography, in addition to more technologically intensive exams (such as MRI and positron-emission tomography;CT), and many general practitioners have ultrasonography machines in their offices and commonly scan the thyroid. Both the government and the media have frequently extolled the virtues of early cancer detection.

Earlier this year, a few physicians presented a different perspective, expressing concern about overdiagnosis of thyroid cancer and suggesting that screening be banned. Major newspapers picked up the story, running headlines asking "Is thyroid cancer overdiagnosed?" There was also widespread broadcast coverage, including special programs devoted to the issue on all three of the country's major television networks. Yet because it is so challenging to adequately explain why early diagnosis and treatment of a common type of cancer could be problematic, thyroid-cancer screening continues to grow in popularity.

Vital statistics and cancer-registry data for South Korea illustrate the effect of screening. Thyroid-cancer incidence increased slowly during the 1990s, then rapidly after the turn of the century (see line graphThyroid-Cancer Incidence and Related Mortality in South Korea, 1993-2011.). In 2011, the rate of thyroid-cancer diagnoses was 15 times that observed in 1993. This entire increase can be attributed to the detection of papillary thyroid cancer. Furthermore, despite the dramatic increase in incidence, mortality from thyroid cancer remains stable ? a combination that is pathognomonic for overdiagnosis.

Variation in thyroid-cancer incidence across the country's 16 administrative regions may be explained by screening penetration (see scatter plotPenetration of Thyroid-Cancer Screening (2008-2009) and Incidence of Thyroid Cancer (2009) in the 16 Administrative Regions of South Korea.). In 2010, the Korean Community Health Survey (the government's annual nationwide health survey) asked adults older than 19 years of age whether they had been screened for thyroid cancer during the previous 2 years. There was a strong correlation between the proportion of the population screened in a region in 2008 and 2009 and the regional incidence of thyroid cancer in 2009. Although the aggregate correlation could be vulnerable to the ecologic fallacy, the finding of significant positive correlations in each of eight age- and sex-based groups suggests that the finding is more robust.

Thyroid cancer is now the most common type of cancer diagnosed in South Korea. More than 40,000 people in the country were diagnosed with the disease in 2011 - a figure that is more than 100 times the number of people who die from thyroid cancer, which for the past decade has been between 300 and 400 each year. Virtually all the people diagnosed with thyroid cancer are treated: roughly two thirds undergo radical thyroidectomy, and one third undergo subtotal thyroidectomy. The tumors being excised are getting smaller - at one center, the proportion of patients undergoing surgery for a tumor measuring less than 1 cm in diameter increased from 14% in 1995 to 56% 10 years later.2 Despite guidelines recommending against evaluation and surgery for tumors less than 0.5 cm in diameter, one quarter of surgical patients now have tumors that fall into this category.

Thyroid-cancer surgery has substantial consequences for patients. Most must receive lifelong thyroid-replacement therapy, and a few have complications from the procedure. An analysis of insurance claims for more than 15,000 Koreans who underwent surgery showed that 11% had hypoparathyroidism and 2% had vocal-cord paralysis.

Pathologists have long recognized the existence of a substantial reservoir of subclinical thyroid cancer. In 1947, a report in the Journal pointed out the discrepancy between the frequent finding of thyroid cancer at autopsy and its rarity as a cause of death.4 It has been estimated that at least one third of adults harbor small papillary thyroid cancers, the vast majority of which will not produce symptoms during a person's lifetime.5 As the South Korean data show, all it takes to expose this reservoir is ultrasonographic screening.

The experience with thyroid-cancer screening in South Korea should serve as a cautionary tale for the rest of the world. During the past two decades, multiple countries have had a substantial increase in thyroid-cancer incidence without a concomitant increase in mortality. According to the Cancer Incidence in Five Continents database maintained by the International Agency for Research on Cancer, the rate of thyroid-cancer detection has more than doubled in France, Italy, Croatia, the Czech Republic, Israel, China, Australia, Canada, and the United States. The South Korean experience suggests that these countries are seeing just the tip of the thyroid-cancer iceberg - and that if they want to prevent their own ¡°epidemic,¡± they will need to discourage early thyroid-cancer detection.


[2015-12-23. Á¶¼±ÀϺ¸] '5ÓÞäß °ËÁø'¡¤³»½Ã°æÀÌ äßȯÀÚ »ì·È´Ù


[2016-9-7. µ¥Àϸ® ¸Þµð] ±¹°¡°ËÁø ´ëÀå¾Ï,À§¾Ï ¹ß°ßÀ² ¸Å³â °¨¼Ò

¸Å¿ì ¸ðÈ£ÇÑ ±â»çÀÔ´Ï´Ù. ¾ÏÀǽÉÀÚ, ¹ß°ßÀ² µî Á¤ÀǸ¦ ¾Ë ¼ö ¾ø´Â ¿ë¾î°¡ ¸¹ÀÌ ¾²ÀÎ ±â»çÀÔ´Ï´Ù. ¿©ÇÏÆ° À§¾Ï ÀÇ½É È¯ÀÚ Áß 1/3 Á¤µµ¸¸ ÃÖÁ¾ÀûÀ¸·Î À§¾ÏÀ¸·Î Áø´ÜµÈ´Ù´Â À̾߱⠰°½À´Ï´Ù.


[2016-2-14. µ¥Àϸ® ¸Þµð] ¼ö¼úµ¿ÀǼ­ '¹«¿ëÁö¹°'¡¦±ÃÁö ¸ô¸®´Â 'ÀÇ»çµé'

±â»çÀÇ ³»¿ëÀº Ãæ°ÝÀûÀÔ´Ï´Ù. »ó¼¼ÇÑ ¼³¸íÀº ¾ø¾úÀ¸³ª °ËÁø¿¡¼­ ¹«Áõ»ó biliary stoneÀÌ ¹ß°ßµÇ¾î ¹º°¡ÀÇ ½Ã¼úÀ» ¹Þ´ø Áß ¾Æ¸¶µµ sedation °ü·ÃÇÏ¿© »ç¸ÁÇÏ¿´´Ù´Â °ÍÀÔ´Ï´Ù. Âü Àλý Ç㹫ÇÕ´Ï´Ù. ¾ÈŸ±õ½À´Ï´Ù. Á¶½ÉÇÏ°í ¶Ç Á¶½ÉÇÒ ÀÏÀÔ´Ï´Ù.

°Ç°­°ËÁøÀ» ÅëÇØ ¹«Áõ»ó ´ã³¶ ¹× ´ã¼®ÀÌ ¹ß°ßµÈ ÃÖ¾¾´Â Bº´¿ø¿¡¼­ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP)¸¦ ¹ÞÀº ÈÄ »ç¸ÁÇß´Ù. ÀÇ·áÁøÀÌ ¹Ì´ÙÁ¹¶÷, ÆäÄ¡µò(¸¶¾à¼ºÁøÅëÁ¦), ÇÁ·ÎÆ÷Æú Åõ¿© ÈÄ ½Ã¼úÀ» ÁøÇàÇÏ´ø Áß È°·Â¡ÈÄ ¹× »ê¼ÒÆ÷È­µµ°¡ ±Þ°ÝÈ÷ ¶³¾îÁ® ½ÉÁ¤Áö°¡ ¹ß»ýÇß°í, ½ÉÆó¼Ò»ý¼ú ÈÄ ÀϽÃÀûÀ¸·Î ½ÉÀåÀÌ ¶Ù¾úÀ¸³ª Àú»ê¼Ò¼º ³ú¼Õ»óÀ» ÀÔ¾ú´Ù. ÀÌÈÄ ÁßȯÀڽǿ¡¼­ ÀΰøÈ£Èí±â Àû¿ë, Àúü¿Â¿ä¹ý µî Áö¼ÓÀûÀÎ ÁýÁß Ä¡·á°¡ ½ÃÇàµÆÀ½¿¡µµ ºÒ±¸ÇÏ°í ³¡³» »ç¸ÁÇß´Ù.


[2016-12-21] ¾Ï ȯÀÚ´Â ÁÙ°í Àִ°¡?

¹Ý°¡¿î (?) ´º½º°¡ ÀÖ¾ú½À´Ï´Ù. ŸÀÌƲÀº "¾Ï ¹ß»ý·ü 3³â ¿¬¼Ó ÁÙ°í 5³â »ýÁ¸À² 70% ³Ñ¾î"ÀÔ´Ï´Ù.

°ú¿¬ ±×·²±î¿ä? "Çѱ¹ ½Å±Ô ¾ÏȯÀÚ 1¸¸¿©¸í ÁÙ¾ú´Âµ¥¡¦¾Ë°í º¸´Ï °©»ó»ù¾ÏÀÇ Âø½Ã"¶ó´Â Á¦¸ñÀÇ °æÇâ½Å¹® ±â»ç°¡ º¸´Ù Á¤È®ÇÏ´Ù°í »ý°¢µË´Ï´Ù.

°©»ó¼±¾Ï °ËÁøÀÌ ÇÊ¿äÇÑ°¡¿¡ ´ëÇÑ »çȸÀû À̽´°¡ ÀÖ¾ú°í, ÀÌÈÄ °©»ó¼±¾Ï °ËÁøÀÌ °¨¼ÒÇÏ¿´½À´Ï´Ù (Âü°í: EndoTODAY °©»ó¼±¾Ï screeningÀÌ ÇÊ¿äÇÑ°¡?). Àüü ¾ÏÀº ÁÙ¾ú½À´Ï´Ù. ±×·±µ¥ °©»ó¼±¾ÏÀ» »©¸é ¾ÏÀÌ ´Ã¾ú½À´Ï´Ù. ÀÌ »óȲ¿¡¼­ ½Å¹® ±â»çÀÇ Å¸ÀÌƲÀ» ¾î¶»°Ô »Ì´Â °ÍÀÌ ¿Ç¾Ò°Ú´ÂÁö »ý°¢ÇØ º¾½Ã´Ù.

Á¤Ã¥´ç±¹¿¡¼­´Â ¾ÏÀÌ °¨¼ÒÇÏ¿´´Ù´Â °á°ú¸¦ º¸°í ½ÍÀ» °ÍÀÔ´Ï´Ù. ±¹¹Îµéµµ ¾ÏÀÌ °¨¼ÒÇÏ¿´´Ù´Â °á°ú¸¦ ±â´Ù¸®°í ÀÖ½À´Ï´Ù. ±×·±µ¥ »ç½ÇÀº ±×·¸Áö°¡ ¾Ê´Ù´Â °ÍÀÌ ¹®Á¦ÀÔ´Ï´Ù. ¾ÏÀº ÁÙÁö ¾Ê¾Ò½À´Ï´Ù.

Á¦ ÀÔÀå¿¡¼­ ´ÙÇàÀÎ °ÍÀº À§¾ÏÀÌ ÁÙ¾ú´Ù´Â °ÍÀÔ´Ï´Ù. ´ëÀå¾Ïµµ ÇÔ²² ÁÙ¾ú´Ù´Â Á¡µµ ÁÁÀº ´º½ºÀÔ´Ï´Ù. ±×·¯³ª Æó¾Ï, À¯¹æ¾Ï, Àü¸³¼±¾Ï, ÃéÀå¾Ï, ´ã³¶ ¹× ±âŸ ´ãµµ¾Ï, ºñÈ£ÁöŲ ¸²ÇÁÁ¾Àº ´Ã¾ú½À´Ï´Ù. ¾ÆÁ÷ ¾ÏÀÌ ÁÙ¾ú´Ù°í ÁÁ¾ÆÇÒ ´Ü°è´Â ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù.


[2016-12-21. ±è»ó±Õ ±³¼ö´Ô ÆíÁö]

Àüü ¾Ï ¼ýÀÚ´Â ´çºÐ°£Àº ´Ã¼ö¹Û¿¡ ¾ø½À´Ï´Ù. °í·É Àα¸°¡ °è¼Ó ´ÃÅ״ϱî¿ä. ¿¬·Éº¸Á¤ ¾ÏȯÀÚ´Â À§¾Ï¿¡¼­ ÀÌ¹Ì °¨¼ÒÇÏ°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ¾Ïµµ ´ëºÎºÐ ±×·¸±¸¿ä.

Á¤È®ÇÑ ÆÑÆ®´Â ÀϹÝÀÎ, ½ÉÁö¾î ¾ÆÁÖ Àü¹®°¡ ¾Æ´Ï¸é ÀÌÇØÇϱ⠾î·Æ°í, ´ëÃæ ¾ó¹ö¹«¸®ÀÚ´Ï ÆÑÆ®°¡ ¾Æ´Ñ ¹®Á¦°¡ ÀÖ°í. ÀÇÇÐÀûÀ¸·Î¸¸ Á¢±ÙÇÒ ¹®Á¦°¡ ¾Æ´Ï°í, »çȸÀû ÇÕÀÇ°¡ ¾î´À Á¤µµ ÇÊ¿äÇÑ ¹®Á¦ÀÔ´Ï´Ù. ¼±»ý´Ô°ú °°Àº ¿ÀÇǴϾ𸮴õÀÇ ÀÔÀåÀÌ ±²ÀåÈ÷ Áß¿äÇÑ ¹®Á¦ÀÔ´Ï´Ù.


[2017-1-8. ¿¬ÇսŹ®] °ËÁø¹Þ´Ù 'Á¶¿µÁ¦ ºÎÀÛ¿ë' »ç¸Á¡¦ÀÇ»ç ÁýÇàÀ¯¿¹

ÀûÀýÇÑ °ËÁøÀ¸·Î Á¶¿µÁ¦ CT¸¦ ¹ÞÀ» ÀÏÀº ¾ø´Â °Í °°½À´Ï´Ù. °úÀ× °ËÁø¿¡ µû¸¥ ¾ÈŸ±î¿î Á×À½À̶ó°í¹Û¿¡ ¸»ÇÒ ¼ö ¾ø³×¿ä.

Á¶¿µÁ¦ ºÎÀÛ¿ëÀ¸·Î ½Ç½ÅÇÑ ÀûÀÌ ÀÖ´Â 70´ë¿¡°Ô °Ç°­°ËÁøÀ» Çϸ鼭 Á¶¿µÁ¦¸¦ Åõ¿©Çϵµ·Ï ÇØ ¼ûÁö°Ô ÇÑ Àǻ簡 1½É¿¡¼­ ÁýÇàÀ¯¿¹¸¦ ¼±°í¹Þ¾Ò´Ù. ºÎ»êÁö¹ý Çü»ç7´Üµ¶ Á¶½Â¿ì ÆÇ»ç´Â ¾÷¹«»ó °ú½ÇÄ¡»ç ÇøÀÇ·Î ±â¼ÒµÈ ÀÇ»ç A ¾¾¿¡°Ô ±Ý°í 1³â¿¡ ÁýÇàÀ¯¿¹ 2³âÀ» ¼±°íÇß´Ù°í 8ÀÏ ¹àÇû´Ù. ¶Ç ¾÷¹«»ó °ú½ÇÄ¡»ç¿Í ÀÇ·á¹ý À§¹ÝÀ¸·Î ±â¼ÒµÈ ¹æ»ç¼±»ç B ¾¾¿¡°Ô´Â ¹ú±Ý 500¸¸¿øÀ» ¼±°íÇß´Ù.

A ¾¾ µîÀÌ ÀÏÇÏ´Â º´¿ø Áø·áÁ¤º¸½Ã½ºÅÛÀº ÀÌ ¾¾°¡ Á¶¿µÁ¦ ºÎÀÛ¿ëÀÌ ÀÖ´Ù´Â »ç½ÇÀ» Æ˾÷âÀ¸·Î ¶ç¿ü±â ¶§¹®¿¡ µÎ »ç¶÷ ¸ðµÎ ÀÌ ¾¾¿¡°Ô Á¶¿µÁ¦ ºÎÀÛ¿ëÀÌ ÀÖ´Ù´Â »ç½ÇÀ» ¾Ë°íµµ ¾÷¹«»ó ÁÖÀÇÀǹ«¸¦ ´ÙÇÏÁö ¾Ê¾Æ ÀÌ ¾¾°¡ »ç¸ÁÇÑ °ÍÀ¸·Î Á¶ ÆÇ»ç´Â ÆÇ´ÜÇß´Ù.


[2017-5-16. Á¶¼±ÀϺ¸] Ò´ 100¸¸¸í ¹Þ´Â À§Àå Á¶¿µ¼ú, À§¾Ï ¸ø ã´Â´Ù

"±¹³»¿¡¼­ À§Àå Á¶¿µ¼ú·Î Á¶±â À§¾ÏÀ» ã¾Æ³»´Â È¿°ú°¡ ÀÛ´Ù´Â ¿¬±¸°¡ ÀÕµû¶ó ³ª¿À¸é¼­ À§Àå Á¶¿µ¼ú °ËÁøÀ» °è¼ÓÇØ¾ß ÇÒÁö¸¦ ³õ°í ³í¶õÀÌ ÀÏ°í ÀÖ´Ù. ´ëºÎºÐ ±¹¹ÎÀÌ ¾Æ¹«·± Áõ»óÀÌ ¾ø´Âµ¥µµ Á¤±â °ËÁøÀ» ¹Þ´Â ÀÌÀ¯´Â ¾ÏÀ» Á¶±â¿¡ Àâ¾Æ³» Á¶±â Ä¡·áÇؼ­ »ç¸Á·üÀ» ³·Ãß±â À§Çؼ­´Ù. ±×·±µ¥ À§Àå Á¶¿µ¼ú °ËÁøÀº Á¶±â À§¾Ï ¹ß°ßÀ²ÀÌ ³·¾Æ À§¾Ï »ç¸Á·üÀ» ³·ÃßÁö ¸øÇÏ´Â °ÍÀ¸·Î ÆľǵƴÙ. ±×·³¿¡µµ ÇÑ ÇØ 100¸¸¸íÀÌ ³Ñ´Â ±¹¹ÎÀÌ °Ç°­ °ËÁø¿¡¼­ À§Àå Á¶¿µ¼úÀ» ÅÃÇÏ°í ÀÖ´Ù."

À§ÀåÁ¶¿µ¼úÀÌ °ËÁø¿¡ µµ¿òµÇÁö ¾Ê´Â´Ù´Â ÀÚ·á°¡ 10³âÀÌ»ó °è¼Ó ¹ßÇ¥µÇ°í Àִµ¥ ¾ÆÁ÷µµ ±¹°¡¾Ï°ËÁø¿¡¼­ À§ÀåÁ¶¿µ¼ú·Î °Ë»ç¹Þ´Â ±¹¹ÎÀÌ ¸¹½À´Ï´Ù. µµ´ëü ´©±¸ À߸øÀΰ¡¿ä? À߸øµÈ Á¤Ã¥À» ¹Ù²Ù´Âµ¥ ¿Ö ÀÌ·¸°Ô ¶äÀ» µéÀÌ´Â °ÍÀϱî¿ä? ±¹¹Î ½º½º·Î ¿ÇÀº ±æÀ» ã¾Æ°¡´Â ¼ö ¹Û¿¡ ¾øÀ» °Í °°½À´Ï´Ù. ÀÚ²Ù ¼¼¿ùÈ£°¡ »ý°¢³³´Ï´Ù.


[2017-6-3. û³âÀÇ»ç] ºñ¿ëÈ¿°ú¼º ¶³¾îÁö´Â ±¹°¡¾Ï°ËÁø, µµ¸¶¡¦À¯¹æ¾Ï, °¡Àå ÀúÁ¶

¿¬¼¼ÀÇ´ë ¿¹¹æÀÇÇб³½Ç ¹ÚÀºÃ¶ ±³¼ö´Â Áö³­ 2ÀÏ ±¹¹Î°Ç°­º¸Çè°ø´Ü°ú ±¹¸³¾Ï¼¾ÅÍ°¡ °øµ¿°³ÃÖÇÑ ¡®¾Ï±Øº¹ Æò»ý°Ç°­ ½ÇÇüÀ» À§ÇÑ °øµ¿ ½ÉÆ÷Áö¾ö¡¯¿¡¼­ ȯÀÚ°¡ 1³â°£ »ý¸íÀ» ¿¬ÀåÇϴµ¥ ÁöºÒÇÏ´Â ºñ¿ëÀ» °è»êÇØ ¸¸µç ¡®±¹°¡¾Ï°ËÁøÀÇ ºñ¿ëÈ¿°ú¡¯¸¦ °ø°³ÇÏ¸ç ¡°À¯¹æ¾Ï °ËÁøÀÌ ´Ù¸¥ ¾Ïµé¿¡ ºñÇØ ºñ¿ëÈ¿°ú¼ºÀÌ ¸Å¿ì ³·°Ô ³ªÅ¸³µ´Ù¡±°í ¼³¸íÇß´Ù. ¹Ú ±³¼ö¿¡ µû¸£¸é À§³»½Ã°æÀ¸·Î ¹ß°ßÇÑ À§¾ÏÀÇ ºñ¿ëÈ¿°ú´Â 990¸¸¿ø, À§ÀåÁ¶¿µÃÔ¿µÀ¸·Î ¹ß°ßÇÑ À§¾ÏÀº 1,743¸¸¿øÀ̾úÀ¸¸ç, ÀڱðæºÎ¾ÏÀº 601¸¸¿øÀÌ´Ù. ¹Ý¸é À¯¹æ¾ÏÀº 3,368¸¸¿øÀ¸·Î ´Ù¸¥ ¾Ï¿¡ ºñÇØ ºñ¿ëÈ¿°ú¼ºÀÌ °¡Àå ³·¾Ò´Ù...... ¶Ç ¡°À§¾ÏÀÇ °æ¿ì °ËÁøÀ² Áõ°¡¿Í »ýÁ¸À² Áõ°¡°¡ À¯ÀǹÌÇÑ °ü°è·Î º¸ÀÌÁö¸¸ À¯¹æ¾ÏÀÇ °æ¿ì¿¡´Â ±×·¸Áö ¾Ê´Ù¡±¸é¼­ ¡°µ¿¾çÀÎÀÇ À¯¹æ¾Ï °ËÁøÀº ÇÏÁö ¾Ê´Â ÆíÀÌ ³´´Ù´Â »ý°¢¸¶Àú µé°Ô ÇÑ´Ù¡±°í ¸»Çß´Ù.

¼­¿ïÀÇ´ë Á¶ºñ·æ ±³¼ö´Â ¡°°ËÁøÀÚü°¡ ¾î¶² »ç¶÷¿¡°Ô´Â µæÀÌ µÇÁö¸¸ ¾î¶² »ç¶÷¿¡°Ô´Â ÇØ°¡ µÉ ¼öµµ ÀÖ´Ù¡±¸é¼­ ¡°ÀÌÁ¦´Â µ¥ÀÌÅ͵µ ¸¹ÀÌ ½×¿´°í °ËÁøÀ» ÇØ µæÀÌ µÇ´Â »ç¶÷°ú ÇØ°¡ µÇ´Â »ç¶÷À» ±¸ºÐÇÒ ¼ö ÀÖ´Â ¼öÁØÀÌ µÆ´Ù. ²À ÇÊ¿äÇÑ »ç¶÷µéÀÌ °ËÁøÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇÑ ¼ö°ËÀÚ ¼±Á¤ÀÌ ÇÊ¿äÇÏ´Ù¡±°í ¸»Çß´Ù.

°ø´Ü ºòµ¥ÀÌÅͿ½Ç ¹ÚÁ¾Çå Àü¹®¿¬±¸À§¿øÀº »çÈÄ°ü¸® Á߿伺À» °­Á¶Çϸç, ÀÌ»ó¼Ò°ßÀ» °¡Áø »ç¶÷µéÀ» Á¤ºÎ°¡ °ü¸®ÇØ¾ß ÇÑ´Ù°í ÁÖÀåÇß´Ù. ¹Ú À§¿øÀº ¡°2015³â ±âÁØÀ¸·Î °ÅÀÇ 1,000¸¸¸íÀÌ ±¹°¡¾Ï°ËÁøÀ» ¹Þ¾Ò°í ±× Áß 3¸¸¸í Á¤µµ°¡ ¾ÏÀÌ ÀǽɵǴ »ç¶÷µéÀ̾ú´Ù¡±¸é¼­ ¡°±×·¯³ª ¸î ¸íÀ̳ª È®ÁøÀ» ¹Þ¾Ò´ÂÁö¿¡ ´ëÇÑ ÀÚ·á°¡ ¾ø´Ù. °ø´Üµµ ÀÌ µ¥ÀÌÅ͸¦ °¡Áö°í ÀÖÁö ¾Ê´Ù¡±°í Åä·ÎÇß´Ù.


[2017-6-25. µ¿¾Æ»çÀ̾ð½º] ¾Æ¹«¸® Àß °ü¸®Çصµ ¾Ï¿¡ °É¸± »ç¶÷Àº °É¸°´Ù?

¿µ±¹¿¡¼­ ¼öÁýµÈ ¾Ï À¯Àüü µ¥ÀÌÅÍ¿Í ÇÔ²² Á» ´õ ÀÚ¼¼È÷ »ìÆ캸¸é, À¯ÀüÀûÀÎ ÀÌÀ¯·Î µ¹¿¬º¯ÀÌ°¡ ÀϾ ¾ÏÀÌ ¹ßº´ÇÑ °æ¿ì´Â ÀüüÀÇ 5%¿¡ ºÒ°úÇß´Ù. ȯ°æÀûÀÎ ÀÌÀ¯·Î µ¹¿¬º¯ÀÌ°¡ ÀϾ °æ¿ìµµ ÀüüÀÇ 3ºÐÀÇ 1¿¡ Á¶±Ý ¸ø ¹ÌÃÆ´Ù(29%). ¹Ý¸é ¹«ÀÛÀ§·Î ÀϾ µ¹¿¬º¯ÀÌ°¡ ¾ÏÀ¸·Î ¹ßÀüÇÑ °æ¿ì´Â ÀüüÀÇ 3ºÐÀÇ 2(66%)¸¦ Â÷ÁöÇÏ´Â °ÍÀ¸·Î È®ÀεƴÙ. ¾ÏÀÇ 3ºÐÀÇ 2´Â Àΰ£ÀÇ ÈûÀ¸·Î´Â ¸·À» ¼ö ¾ø´Â ¾ÏÀ̶ó´Â ¶æÀÌ´Ù.

ÀÌ´Â ±×µ¿¾È ¹«ÀÛÀ§ ¿äÀÎÀÌ ²Ï ¸¹Àº ºÎºÐÀ» Â÷ÁöÇÒ °ÍÀÌ¶ó ¿¹»óÇÏ°í ÀÖ´ø ¿¬±¸Àڵ鿡°Ôµµ ³î¶ó¿î ¼öÄ¡¿´´Ù. ƯÈ÷ Èí¿¬À̳ª °£Á¢Èí¿¬ °°Àº ȯ°æÀûÀÎ ¿äÀο¡ ¿µÇâÀ» ¸¹ÀÌ ¹ÞÀ» ÁÙ ¾Ë¾Ò´ø Æó¾Ïµµ 3ºÐÀÇ 1 °¡·®Àº ¹«ÀÛÀ§ ¿äÀÎÀ¸·Î ¹ß»ýÇÑ´Ù´Â °Ô Ãæ°ÝÀûÀ̾ú´Ù. ÃéÀå, ³ú, »À, Àü¸³¼±°ú °°Àº Á¶Á÷ÀÇ ¾ÏÀº ¹«ÀÛÀ§ ¿äÀο¡ ÀÇÇØ »ý±æ È®·üÀÌ Æ¯È÷ ³ô¾Ò´Ù.


[2018-2-6] °ÇÁø CT ºÎÀÛ¿ë »ç·Ê

°ËÁø¹Þ´Ù 'Á¶¿µÁ¦ ºÎÀÛ¿ë' »ç¸Á ±â»ç¸¦ º¸¾Ò½À´Ï´Ù. °Ç°­°ËÁøÀº ¸Å¿ì À§ÇèÇÑ procedure¶ó°í »ý°¢ÇÕ´Ï´Ù. ²À ÇÊ¿äÇÑ °æ¿ì¸¸ ÃÖ¼ÒÇÑÀ¸·Î ½ÃÇàÇÏ´Â Áß¿ä °Ë»ç°¡ °Ç°­°ËÁøÀÔ´Ï´Ù. ±×³É ¾Æ¹«³ª ¾Æ¹« ¶§³ª ÇÒ ±×·² ¼ºÁúÀÌ ¾Æ´Õ´Ï´Ù. À§ÇèÇϴϱî.

[2019-7-6] °úÀ× °ËÁø

[Medical Observer] Æó¾Ï°ËÁø ¹ÞÀº 1000¸í Áß 351¸í '°¡Â¥ ¾Ï ȯÀÚ' µÈ´Ù"

À̹ø ´ÞºÎÅÍ ½ÃÇàµÇ´Â ±¹°¡ Æó¾Ï°ËÁøÀ» Áï°¢ Áß´ÜÇ϶ó´Â ÇаèÀÇ ¸ñ¼Ò¸®°¡ ³ô¾ÆÁö°í ÀÖ´Ù. ¾Ï°ËÁøÀ¸·Î Æó¾ÏÀ» Á¶±â¹ß°ßÇØ »ýÁ¸À²µµ ³ô¾ÆÁú °ÍÀ̶õ Á¤ºÎÀÇ Áø´Ü°ú ´Þ¸®, Èí¿¬ÀÚÀÇ ½ÇÁúÀûÀÎ »ç¸Á·ü °¨¼Ò´Â ±â´ëÇϱ⠾î·Æ°í ¿ÀÈ÷·Á °¡Â¥ ¾Ï ȯÀÚ¸¦ ´ë·® ¾ç»êÇÒ ¿ì·Á°¡ ÀÖ´Ù´Â °ÍÀÌ´Ù. °Ô´Ù°¡ ¼¼°èÀûÀ¸·Î Æó¾Ï°ËÁøÀ» ±¹°¡ÀûÀ¸·Î ½Ç½ÃÇÏ´Â ³ª¶ó´Â ¾øÀ¸¸ç, Æó¾Ï°ËÁøÀ¸·Î Æó¾Ï »ç¸Á·üÀ» ³·Ãá´Ù´Â Á¤ºÎÀÇ È«º¸´Â Åë°è ¼öÄ¡¸¦ ÀÌ¿ëÇÑ ¸í¹éÇÑ ±â¸¸À̶ó´Â ÁÖÀåÀÌ´Ù.

°úÀ×Áø´Ü¿¹¹æ¿¬±¸È¸(ȸÀå ÀÌÁ¤±Ç)´Â 3ÀÏ Çѱ¹ÇÁ·¹½º¼¾ÅÍ¿¡¼­ '±¹°¡ Æó¾Ï°ËÁø¿¡ ´ëÇÑ ±âÀÚȸ°ß'À» ¿­°í "°¡Â¥È¯ÀÚ¸¦ ¾ç¼ºÇÏ´Â ±¹°¡ Æó¾Ï°ËÁøÀ» Áß´ÜÇ϶ó"°í Ã˱¸ÇÏ°í ³ª¼¹´Ù. ¿¬±¸È¸ ÀÌÁ¤±Ç ȸÀå(»ï¼º¼­¿ïº´¿ø °¡Á¤ÀÇÇаú ±³¼ö)Àº "¼¼°èÀÇÇÐȸÀÇ¿¡¼­µµ Æó¾Ï°ËÁøÀÇ È¿°ú¿¡ ´ëÇÑ °Ý·ÄÇÑ ³í¶õÀÌ °è¼ÓµÇ°í ÀÖ´Ù. ÀÌ·± »óȲ¿¡¼­ ¼²ºÎ¸£°Ô ±¹°¡°¡ ³ª¼­¼­ ¾î¼³Ç Æó¾Ï°ËÁøÀ» ±¹¹Î¿¡°Ô °­¿äÇÏ´Â °ÍÀº Ä¿´Ù¶õ ¿ÀÆÇ"À̶ó¸ç "Æó¾Ï°ËÁøÀ» ±¹°¡¾Ï°ËÁø¿¡ Æ÷ÇÔÇØ °­¾ÐÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ´Â Á¤Ã¥ÀÌ ¾Æ´Ï´Ù. Á¤ºÎ´Â ¼¼°è ÃÖÃÊ ±¹°¡ Æó¾Ï°ËÁøÀ̶ó´Â ¼º°ú¿¡ ÁýÂøÇØ ±¹¹Î°Ç°­¿¡ ¸·´ëÇÑ ¿µÇâÀ» ³¢Ä¡´Â Á¤Ã¥À» ÃßÁøÇؼ­´Â ¾È µÈ´Ù"°í °­Á¶Çß´Ù.

¿¬±¸È¸´Â ¸ÕÀú Á¤ºÎ°¡ Æó¾Ï°ËÁøÀ¸·Î »ç¸Á·üÀ» ³·Ãâ ¼ö ÀÖ´Ù´Â ÁÖÀå¿¡ ´ëÇØ È²´çÇÑ ³í¸®¶ó°í ²¿Áý¾ú´Ù. Á¤ºÎ´Â Èí¿¬ÀÚ°¡ Àú¼±·® ÈäºÎCT·Î Æó¾Ï°ËÁøÀ» ¹ÞÀ¸¸é Æó¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á·üÀ» 20% ³·Ãâ ¼ö ÀÖ´Ù°í ¾Ë·È´Ù. ÇÏÁö¸¸ ±× ±Ù°Å ³í¹®À» º¸¸é, Æó¾ÏÀ¸·Î ÀÎÇÑ »ó´ëÀû »ç¸Á·üÀÌ 20% °¨¼ÒÇÑ °ÍÀ¸·Î Àý´ëÀû »ç¸Á·ü °¨¼Ò´Â 1%p(5%¡æ4%)¿¡ ºÒ°úÇÏ´Ù(N Engl J Med 2011). ¶Ç Àú¿ë·® ÈäºÎCT°¡ Æó¾Ï »ç¸Á·üÀ» ÁÙÀÏ ¼ö ÀÖ´Ù°í °á·Ð ³»¸° ¿¬±¸´Â ÀÌ ³í¹®ÀÌ À¯ÀÏÇÏ´Ù. ÀÌ È¸ÀåÀº "ÀÌ´Â Åë°è ¼öÄ¡¸¦ ÀÌ¿ëÇÑ ¸í¹éÇÑ ±â¸¸"À̸ç "Æó¾Ï°ËÁøÀÇ È¿°ú¸¦ ºÎÇ®¸®°í À§ÇèÀ» °¨Ãß·Á´Â ¾âÆÅÇÑ ¼úÃ¥¿¡ ºÒ°úÇÏ´Ù"°í ÁöÀûÇß´Ù.

¿¬±¸È¸´Â ¾Ï°ËÁøÀÇ Áß¿äÇÑ À§ÇèÀº °ËÁøÀ¸·Î ÀÎÇÑ 2Â÷ ÇÇÇØ¿¡ ÀÖ´Ù°í °­Á¶Çß´Ù. ¾ç¼º°áÀýÀÎ °¡Â¥ Æó¾Ï ȯÀÚ¿Í °ú´ÙÁø´ÜµÈ ¾Ï ȯÀÚ´Â, Æó¾Ï°ËÁøÀ» ¹ÞÁö ¾Ê¾Ò´Ù¸é ÇÏÁö ¾Ê¾Æµµ µÉ Ãß°¡ °Ë»ç¿Í ¼ö¼ú¡¤Ç×¾ÏÄ¡·á¸¦ ¹Þ¾Æ¾ß ÇÏ´Â »óȲÀÌ ¹ß»ýÇÑ´Ù´Â °ÍÀÌ´Ù. ±× °úÁ¤¿¡¼­ µå¹°Áö¸¸ »ç¸Á¿¡µµ À̸£´Â µî ¾öû³­ ÇÇÇظ¦ °æÇèÇÏ°Ô µÈ´Ù´Â °Ô ¿¬±¸È¸ ÁÖÀåÀÌ´Ù. ¾Õ¼­ Æó¾Ï°ËÁøÀÇ ÇýÅÃÀ» °­Á¶ÇÑ ¿¬±¸ °á°ú¸¦ ±Ù°Å·Î Æó¾Ï°ËÁøÀÇ À̵æ°ú À§Çظ¦ ÆÇ´ÜÇϸé, Æó¾Ï°ËÁøÀ» ¹ÞÀº 1000¸í Áß 351¸íÀÌ À§¾ç¼º, Áï °¡Â¥ ¾Ï ȯÀÚ·Î È®ÀεȴÙ. ÀÌ Áß Ä§½ÀÀû ÃßÀû°Ë»ç·Î 3¸íÀº ÇÕº´ÁõÀÌ ¹ß»ýÇÏ°í 1¸íÀº »ç¸ÁÇÑ °ÍÀ¸·Î º¸°íµÈ´Ù. Æó¾ÏÀ¸·Î Áø´ÜµÈ 40¸í Áß 7¸íÀº Æó¾Ï°ú »ó°ü¾øÀÌ °úÀ×Áø´ÜÀ¸·Î ÀÎÇØ »ç¸ÁÇßÀ¸¸ç 3¸í¸¸ÀÌ °ËÁø¿¡ µû¸¥ À̵æÀÌ ÀÖ¾ú´Ù.

¼­¿ï¼º¸ðº´¿ø ÀÌÀçÈ£ ±³¼ö(°¡Á¤ÀÇÇаú)´Â "°¡Â¥ Æó¾Ï ȯÀÚµéÀÌ ÃßÀû°Ë»ç³ª È®Áø°Ë»ç¸¦ ¹Þ´Â °úÁ¤¿¡¼­ ¿¹»óµÇ´Â ¾öû³­ ½É¸®Àû, ½ÅüÀû, °æÁ¦Àû ÇÇÇØ¿¡ ´ëÇؼ­´Â ¾Æ¹«·± ´ëÃ¥ÀÌ ¾ø´Ù"¸ç "Àú¼±·® ÈäºÎCT °Ë»ç·Î ¹ß°ßµÈ Á¶±âÆó¾ÏÀÇ 18~67%´Â °úÀ×Áø´ÜÀ̶ó´Â ÃßÁ¤ÀÌ ÀÖÀ½À» °í·ÁÇßÀ» ¶§ °ËÁøÀÇ È¿°ú¼º¿¡ Àǹ®ÀÌ µç´Ù"°í ÁöÀûÇß´Ù. ÀÌ¾î ¿¬±¸È¸´Â 2019³â 7¿ù ÇöÀç ±¹°¡°¡ ±¹¹Î¿¡°Ô °ø½ÄÀûÀ¸·Î Æó¾Ï°ËÁøÀ» ±ÇÇÏ´Â ³ª¶ó´Â ¼¼°è ¾îµð¿¡µµ ¾ø´Ù°í ÇÇ·ÂÇß´Ù. ¹Ì±¹, À¯·´, ÀϺ» µî¿¡¼­ °¢ ±¹°¡ ½ÇÁ¤¿¡ ¸Â´Â ÃÖÀûÈ­µÈ Æó¾Ï°ËÁø¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼ö½Ê ³â°£ ÇØ¿ÔÁö¸¸ ±¹°¡ÀûÀ¸·Î À̸¦ ±Ç°íÇÏÁö ¾Ê´Â´Ù. ¹Ì±¹Áúº´¿¹¹æ¼­ºñ½ºÅ×½ºÅ©Æ÷½º(USPSTF)´Â 2014³â Æó¾Ï°ËÁøÀ¸·Î Àú¿ë·® ÈäºÎCT¸¦ ÃßõÇßÁö¸¸(Grade B) ÀÌ´Â ¹Ì±¹ Á¤ºÎÀÇ °ø½ÄÀûÀÎ ÀÇ°ßÀ¸·Î º¼ ¼ö ¾ø´Ù´Â °Ô ¿¬±¸È¸ ¼³¸íÀÌ´Ù. ¾Æ¿ï·¯ ¿¬±¸È¸´Â Áö³­ÇØ Ã³À½À¸·Î Æó¾Ï°ËÁøÀÇ À¯È¿¼º¿¡ ´ëÇÑ ±¹³» ½Ã¹ü»ç¾÷À» ¸¶ÃÆÀ» »Ó, °á°ú¿¡ ´ëÇØ ÀÇ·á°è¿¡¼­Á¶Â÷ Á¦´ë·Î ³íÀǵÇÁö ¾Ê¾Ò´Ù°í ²¿Áý¾ú´Ù. Á¤ºÎ´Â 2017~2018³â ±¹¸³¾Ï¼¾ÅÍ ÁÖ°üÀ¸·Î Æó¾Ï°ËÁø ½Ã¹ü»ç¾÷À» ½ÃÇàÇØ °ËÁø È¿°ú¸¦ Æò°¡Çß´Ù. ÃÖÁ¾ »ç¾÷ °á°ú¿¡¼­ È®ÀÎµÈ Æó¾Ï ¹ß°ßÀ²Àº 0.56%´Ù. ÇÏÁö¸¸ ÀÌ´Â ÀϺ», ´ë¸¸, ¹Ì±¹ÀÇ Àú¼±·® ÈäºÎ CT¿¡ µû¸¥ Æó¾Ï ¹ß°ßÀ²ÀÌ °¢°¢ 1.5%, 2.34%, 1.03%ÀÎ Á¡À» ºñÃ纸¸é ³·Àº ¼öÁØÀÌ´Ù.

¾È¾Ïº´¿ø ½Å»ó¿ø ±³¼ö(Á¾¾ç³»°ú)´Â "Æó¾Ï°ËÁøÀ» ÅëÇÑ Æó¾Ï ¹ß°ßÀ²ÀÌ ³·¾Æ ¿ì¸®³ª¶ó¿¡¼­ Æó¾Ï°ËÁøÀ» ±¹°¡ÀûÀ¸·Î ½Ç½ÃÇϱ⠾î·Æ´Ù´Â °Ô ¿©·¯ ÇÐÀÚÀÇ ÀÇ°ß"À̶ó¸ç "¼¼°èÀûÀ¸·Î °¢ ±¹°¡¿¡ ¸Â´Â Æó¾Ï°ËÁøÀÌ ¹«¾ùÀÎÁö ¿¬±¸ÇÏ°í ÀÖ´Ù. 0.56%¶ó´Â Å͹«´Ï ¾øÀÌ ³·Àº ¹ß°ßÀ²¸¸À¸·Î ±¹°¡ Æó¾Ï°ËÁøÀ» ÁøÇàÇÒ ¼ö ¾ø´Ù"°í ÁöÀûÇß´Ù. À̾î "Àü ¼¼°èÀûÀ¸·Î Æó¾Ï°ËÁø¿¡ ´ëÇÑ ³íÀÇ°¡ ½ÃÀÛµÈ ´Ü°è"¶ó¸é¼­ "¿ì¸®³ª¶ó¸¸ÀÇ ¹®Á¦°¡ ¾Æ´Ï´Ù. ¼¼°èÀûÀÎ ÃßÀ̸¦ ºÁ Á¶½É½º·´°Ô Æó¾Ï°ËÁøÀ» °í·ÁÇØ¾ß ÇÏ¸ç °ü·Ã ±¹³» ¿¬±¸µµ ÇÊ¿äÇÏ´Ù. ±¹°¡ Æó¾Ï°ËÁøÀ» ½ÃÇàÇÏ°Ú´Ù°í ¹Ð¾îºÙÀÏ »óȲÀÌ ¾Æ´Ï´Ù"°í µ¡ºÙ¿´´Ù.

Ãâó : ¸ÞµðÄ®¾÷Àú¹ö(http://www.monews.co.kr)


[2019-8-1. û³â ÀÇ»ç] º¹ÁöºÎ, ¡®±ÔÁ¦ Á¤ºÎ ÀÔÁõ Ã¥ÀÓÁ¦¡¯·Î 75°Ç ±ÔÁ¦ °³¼± °úÁ¦ ¼±Á¤. 2021³â »ó¹Ý±â ´ëÀå¾Ï 1Â÷ °ËÁø¿¡ ´ëÀå³»½Ã°æ µµÀÔ °ËÅä

±¹°¡ ´ëÀå¾Ï °ËÁøÁ¦µµµµ °³¼±ÇÑ´Ù. ÇöÀç´Â 1Â÷ °ËÁø¿¡¼­´Â ºÐº¯ÀáÇ÷°Ë»ç¸¸ ÀÎÁ¤ÇÏ°í °Ë»ç °á°ú¿¡ µû¶ó 2Â÷ °ËÁø ½Ã ´ëÀå³»½Ã°æ °Ë»ç¸¦ ¹ÞÀ» ¼ö ÀÖ´Ù. ÇÏÁö¸¸ ¿À´Â 2021³â »ó¹Ý±â¿¡´Â ºÐº°ÀáÇ÷°Ë»ç ¿Ü¿¡ ´ëÀå³»½Ã°æ °Ë»çµµ 1Â÷ °ËÁø¹æ¹ýÀÇ Çϳª·Î µµÀÔÇÒ °èȹÀÌ´Ù. ´Ü, Áö³­ 7¿ùºÎÅÍ ¿À´Â 2020³â 12¿ù±îÁö ÁøÇàµÇ´Â ´ëÀå³»½Ã°æ°Ë»ç ½Ã¹ü»ç¾÷¿¡¼­ ¾ÈÀü¼º°ú È¿°ú¼ºÀÌ È®ÀεÇÁö ¾ÊÀ¸¸é ÇöÇà °Ë»ç ¹æ½ÄÀ» À¯ÁöÇÒ ¼ö ÀÖ´Ù°í Çß´Ù.


[References]

1) EndoTODAY °ÇÁø ³»½Ã°æ

2) Minsoo Jung. National Cancer Screening Programs and Evidence-Based Healthcare Policy in South Korea. Health Policy (2014)

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.